Stengone Carmine N., CEO and President of Contineum Therapeutics, Inc. ($CTNM), made three open market sales of company shares over the last 365 days, totaling about $120 thousand. His most recent sale occurred on February 25, 2026. With no open market purchases, his sales rank 9,310th out of 11,678 insiders in the database, well below the average of $8.6 million and 6.4 transactions per insider.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 25, 2026 | Contineum Therapeutics, Inc. | $CTNM | Stengone Carmine N. | CEO and President | M | Stock Option (right to buy) | 2700 | $0.00 | 120,917.0000 | 28,115,548 | 2.18% | 0.01% |
| Feb. 24, 2026 | Contineum Therapeutics, Inc. | $CTNM | Stengone Carmine N. | CEO and President | M | Class A Common Stock | 4400 | $1.26 | 19,354.0000 | 28,115,548 | 29.42% | 0.02% |
| Feb. 24, 2026 | Contineum Therapeutics, Inc. | $CTNM | Stengone Carmine N. | CEO and President | M | Stock Option (right to buy) | 4400 | $0.00 | 123,617.0000 | 28,115,548 | 3.44% | 0.02% |
| Feb. 25, 2026 | Contineum Therapeutics, Inc. | $CTNM | Stengone Carmine N. | CEO and President | S | Class A Common Stock | 2700 | $16.02 | 14,954.0000 | 28,115,548 | 15.29% | 0.01% |
| Feb. 25, 2026 | Contineum Therapeutics, Inc. | $CTNM | Stengone Carmine N. | CEO and President | M | Class A Common Stock | 2700 | $1.26 | 17,654.0000 | 28,115,548 | 18.06% | 0.01% |
| Feb. 24, 2026 | Contineum Therapeutics, Inc. | $CTNM | Stengone Carmine N. | CEO and President | S | Class A Common Stock | 4400 | $16.02 | 14,954.0000 | 28,115,548 | 22.73% | 0.02% |
| Feb. 11, 2026 | Contineum Therapeutics, Inc. | $CTNM | Stengone Carmine N. | CEO and President | S | Class A Common Stock | 400 | $16.00 | 14,954.0000 | 28,115,548 | 2.61% | 0.00% |
| Feb. 11, 2026 | Contineum Therapeutics, Inc. | $CTNM | Stengone Carmine N. | CEO and President | M | Class A Common Stock | 400 | $1.26 | 15,354.0000 | 28,115,548 | 2.67% | 0.00% |
| Feb. 11, 2026 | Contineum Therapeutics, Inc. | $CTNM | Stengone Carmine N. | CEO and President | M | Stock Option (right to buy) | 400 | $0.00 | 128,017.0000 | 28,115,548 | 0.31% | 0.00% |
| Jan. 30, 2026 | Contineum Therapeutics, Inc. | $CTNM | Stengone Carmine N. | CEO and President | A | Stock Option (right to buy) | 445000 | $0.00 | 445,000.0000 | 28,115,548 | 9999.99% | 1.58% |
| April 1, 2025 | KIORA PHARMACEUTICALS INC | $KPRX | Stengone Carmine N. | Director | A | Stock Option (right to buy) | 20000 | $0.00 | 20,000.0000 | 3,000,788 | 9999.99% | 0.67% |
| Jan. 31, 2025 | Contineum Therapeutics, Inc. | $CTNM | Stengone Carmine N. | CEO and President | A | Stock Option (right to buy) | 300000 | $0.00 | 300,000.0000 | 19,352,859 | 9999.99% | 1.55% |
| Sept. 11, 2024 | KIORA PHARMACEUTICALS INC | $KPRX | Stengone Carmine N. | Director | P | Common Stock | 1250 | $3.68 | 1,250.0000 | 2,970,545 | 9999.99% | 0.04% |
| July 1, 2024 | KIORA PHARMACEUTICALS INC | $KPRX | Stengone Carmine N. | Director | A | Stock Option (right to buy) | 1778 | $0.00 | 1,778.0000 | 2,970,545 | 9999.99% | 0.06% |
| May 24, 2024 | Contineum Therapeutics, Inc. | $CTNM | Stengone Carmine N. | CEO and President | A | Stock Option (right to buy) | 285000 | $0.00 | 285,000.0000 | 2,308,972 | 9999.99% | 12.34% |